Learn about Research & Clinical Trials

Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy)

Study Purpose

Evaluate the feasibility of performing a multi-elemental imaging analysis of lung specimens from patients with ILDs, with an technology named LIBS (Laser Induced-Breakdown Spectroscopy)

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patient with ILD.
  • - Patient informed, and agreed to participate.

Exclusion Criteria:

  • - Patient opposed to participating in the study.
  • - Patient without available specimen.
- Patient under legal protection

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03901196
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University Hospital, Grenoble
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Benoit Busser, PharmD, PhD
Principal Investigator Affiliation Grenoble Alpes University Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis
Additional Details

There is a major health problem due to the environmental and occupational related exposures to mineral particles, metals, and dust. The impact on health is considerable in terms of prevalence, morbidity and healthcare costs. Pathologists rarely report the presence of a possible mineral or metal-related etiology in a specimen by lack of available and convenient technology. Therefore, several respiratory diseases are considered idiopathic. Interstitial lung disease (ILD), also known as diffuse parenchymal lung disease (DPLD) is a group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs). In France, 15.000 new cases of ILD are diagnosed each year. ILD may be classified according to the cause. Idiopathic ILD are ILD of unknown causes. The most frequent idiopathic ILD are sarcoidosis and idiopathic pulmonary fibrosis (IPF).These two diseases are the core topic of the present study since they may relate to important mineral or metal exposure. The overall goal of this MEDICO-LIBS study is to evaluate the feasibility of using a laser-induced breakdown spectroscopy (LIBS)-based instrument to image(ie, identify, localize and possibly quantify) metals within selected human specimens with ILDs.

Arms & Interventions

Arms

: Interstitial Lung Disease

Ex : sarcoidosis, IPF

Interventions

Diagnostic Test: - Elemental analysis

LIBS multi elemental analysis of the specimen

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Grenoble Alpes University Hospital, Grenoble, France

Status

Recruiting

Address

Grenoble Alpes University Hospital

Grenoble, , 38043

Site Contact

Vincent Bonneterre, MD, PhD

VBonneterre@chu-grenoble.fr

+33 4 76 76 89 39

CHRU de LILLE, Lille, France

Status

Not yet recruiting

Address

CHRU de LILLE

Lille, , 59000

Site Contact

Cecile Chenivesse, MD, PhD

cecile.chenivesse@chru-lille.fr

+33 4 76 76 89 39

CHU de Lyon HCL - GH Sud, Lyon, France

Status

Not yet recruiting

Address

CHU de Lyon HCL - GH Sud

Lyon, , 69310

Site Contact

Nathalie Freymond, MD

nathalie.freymond@chu-lyon.fr

+33 4 76 76 89 39

Hôpital Louis Pradel, Lyon, France

Status

Not yet recruiting

Address

Hôpital Louis Pradel

Lyon, , 69677

Site Contact

Vincent Cottin, MD, PhD

vincent.cottin@chu-lyon.fr

+33 4 76 76 89 39